N
Niklas Mattsson
Researcher at Lund University
Publications - 209
Citations - 17937
Niklas Mattsson is an academic researcher from Lund University. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 62, co-authored 207 publications receiving 13428 citations. Previous affiliations of Niklas Mattsson include Veterans Health Administration & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson,Henrik Zetterberg,Oskar Hansson,Niels Andreasen,Lucilla Parnetti,Michael Jonsson,Sanna-Kaisa Herukka,Wiesje M. van der Flier,Marinus A. Blankenstein,Michael Ewers,Kenneth Rich,Elmar Kaiser,Marcel M. Verbeek,Magda Tsolaki,Ezra Mulugeta,Erik Rosén,Dag Aarsland,Pieter Jelle Visser,Johannes Schröder,Jan Marcusson,Mony J. de Leon,Harald Hampel,Philip Scheltens,Tuula Pirttilä,Anders Wallin,Maria Eriksdotter Jönhagen,Lennart Minthon,Bengt Winblad,Kaj Blennow +28 more
TL;DR: This multicenter study found that CSF Abeta42, T-t Tau, and P-tau identify incipient AD with good accuracy, but less accurately than reported from single-center studies.
Journal ArticleDOI
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Shorena Janelidze,Niklas Mattsson,Sebastian Palmqvist,Ruben Smith,Thomas G. Beach,Geidy E. Serrano,Xiyun Chai,Nicholas K. Proctor,Udo Eichenlaub,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Eric M. Reiman,Erik Stomrud,Jeffrey L. Dage,Oskar Hansson +15 more
TL;DR: Plasma P-tau18 level increased with progression of Alzheimer’s disease (AD) and differentiated AD dementia from other neurodegenerative diseases, supporting its further development as a blood-based biomarker for AD.
Journal ArticleDOI
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Thomas K. Karikari,Tharick A. Pascoal,Tharick A. Pascoal,Nicholas J. Ashton,Shorena Janelidze,Andrea Lessa Benedet,Juan Lantero Rodriguez,Mira Chamoun,Melissa Savard,Min Su Kang,Min Su Kang,Joseph Therriault,Michael Schöll,Gassan Massarweh,Jean-Paul Soucy,Kina Höglund,Kina Höglund,Gunnar Brinkmalm,Niklas Mattsson,Sebastian Palmqvist,Serge Gauthier,Erik Stomrud,Henrik Zetterberg,Henrik Zetterberg,Henrik Zetterberg,Oskar Hansson,Pedro Rosa-Neto,Pedro Rosa-Neto,Kaj Blennow,Kaj Blennow +29 more
TL;DR: Blood p-tau181 can predict tau and amyloid β pathologies, differentiate Alzheimer's disease from other neurodegenerative disorders, and identify Alzheimer's Disease across the clinical continuum.
Journal ArticleDOI
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Sebastian Palmqvist,Michael Schöll,Michael Schöll,Olof Strandberg,Niklas Mattsson,Erik Stomrud,Henrik Zetterberg,Henrik Zetterberg,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Susan M. Landau,William J. Jagust,Oskar Hansson +13 more
TL;DR: It is suggested that Aβ fibrils start to accumulate predominantly within certain parts of the DMN in preclinical AD and already then affect brain connectivity before neurodegeneration occurs.
Journal ArticleDOI
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Giovanni B. Frisoni,Marina Boccardi,Frederik Barkhof,Kaj Blennow,Kaj Blennow,Stefano F. Cappa,Stefano F. Cappa,Konstantinos Chiotis,Jean-François Démonet,Valentina Garibotto,Panteleimon Giannakopoulos,Anton F. Gietl,Oskar Hansson,Karl Herholz,Clifford R. Jack,Flavio Nobili,Flavio Nobili,Agneta Nordberg,Agneta Nordberg,Heather M. Snyder,Mara ten Kate,Andrea Varrone,Emiliano Albanese,Stefanie I. Becker,Patrick M.M. Bossuyt,Maria C. Carrillo,Chiara Cerami,Bruno Dubois,Valentina Gallo,Ezio Giacobini,Gabriel Gold,Samia Hurst,Anders Lönneborg,Karl-Olof Lövblad,Niklas Mattsson,José-Luis Molinuevo,Andreas U. Monsch,Urs Peter Mosimann,Alessandro Padovani,Agnese Picco,Agnese Picco,Corinna Porteri,Osman Ratib,Laure Saint-Aubert,Charles Scerri,Charles Scerri,Philip Scheltens,Jonathan M. Schott,Ida Sonni,Ida Sonni,Stefan J. Teipel,Stefan J. Teipel,Paolo Vineis,Pieter Jelle Visser,Pieter Jelle Visser,Yutaka Yasui,Bengt Winblad,Bengt Winblad +57 more
TL;DR: A strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers is developed.